Dr. Reddy’s Laboratories Acquires Progynova and Cyclo-Progynova Trademarks from Mercury Pharma Group
Key Highlights: Implications: Dr. Reddy’s gains immediate leadership in the estradiol segment, leveraging its physician network to rapidly expand gynecology prescriptions...
Key Highlights: Implications: Anyra smashes Eylea pricing barriers, flooding retina clinics with budget-friendly therapy that keeps patients compliant for years. Zydus seizes op...
Key Highlights: Implications: DaVitri addresses India’s IVF success rates (30-35% vs. global 50%+), potentially doubling clinic throughput in the $2B+ fertility market expanding...
Emerging Technology Trends in Biopharma The intersection of technology and biopharma isn’t a futuristic idea anymore it’s happening right now. Artificial intelligence (...
Key Highlights: Implications: The Ayush Grid and My Ayush portal move traditional medicine closer to mainstream digital health, creating a unified infrastructure that can plug in...
Key Highlights: Implications: Lilly’s India manufacturing bet locks in low-cost production muscle, outflanking China-dependent rivals as Mounjaro mania drives capacit...
Key Highlights: Implications: PEPAIR smashes cost barriers to OPEP therapy, handing pulmonologists a game-changing tool that slots perfectly alongside Zydus inhalers and Deriphyllin....
Key Highlights: Implications: Sanofi’s Hyderabad bet signals all-in pharma offshoring, vacuuming up AI/data talent that smaller players can’t touch while crushi...
Key Highlights: Implications: India’s GATINN catapults Servier into SPC dominance, crushing fragmented chronic therapy rivals while exploding patient compliance across emerging marke...
Key Highlights: Implications: Imfinzi storms endometrial cancer protocols, giving oncologists a potent immunotherapy combo that leapfrogs chemo-only standards. AstraZeneca doubles do...
